LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) is investigating potential claims on behalf of investors of BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) concerning the Company and its officers’ possible violations of federal securities laws.
On March 16, 2017, BioAmber disclosed its financial results for the 2016 fiscal year, revealing that the Company had failed to meet its predicted revenue forecast by $1.3 million. Among other things, the Company’s President Fabrice Orecchioni blamed the disappointing results on “pricing pressures” and “a disruption from a large customer.” Following this news, BioAmber stock declined, falling to just $2.16 per share as of April 3, 2017.
Then, on March 31, 2017, the Company announced that Mario Saucier would cease serving as the Company’s Chief Financial Officer. On this news, the Company’s share price fell approximately 6% during intraday trading on April 3, 2017, thereby injuring investors.
If you purchased BioAmber securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.